Lincoln doctor’s own experience with spinal cord injury helps him treat patients
A Lincoln doctor who suffered a spinal cord injury now leads a spinal cord injury unit, and tries to be open with his ...
Hosted on MSN1mon
Antibody leads to enhanced motor function in spinal cord injury patients: Clinical trial
More information: Norbert Weidner et al, Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre ...
NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and ...
BioWorld5d
CD36 inhibition ameliorates spinal cord injury
Spinal cord injury (SCI) is a condition affecting the central nervous system characterized by both motor and sensory impairment. SCI causes lipid accumulation in the form of lipid droplets, which may ...
Elon Musk's Neuralink partners with local university for clinical trial
The university will become the second U.S.-based site for Neuralink's Precise Robotically Implanted Brain-Computer Interface ...
The Globe and Mail1mon
Spinal Cord Injury Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight
The severity of Spinal cord injury depends on the location and extent of damage. Injuries to the cervical spine can result in quadriplegia, affecting all four limbs, whereas injuries to the ...
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...
Tiziana Life Sciences Shares Higher on Positive Results for Spinal Cord Injury Treatment
Shares of Tiziana Life Sciences rose after the company said it received positive results from its nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury. The stock was up 5.3% to 84 cents ...